210 related articles for article (PubMed ID: 33164569)
21. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Kim DW; Garon EB; Jatoi A; Keefe DM; Lacouture ME; Sonis S; Gernhardt D; Wang T; Giri N; Doherty JP; Nadanaciva S; O'Connell J; Sbar E; Cho BC
Lung Cancer; 2017 Apr; 106():76-82. PubMed ID: 28285698
[TBL] [Abstract][Full Text] [Related]
22. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
[TBL] [Abstract][Full Text] [Related]
23. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
24. Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.
Zhang YQ; Jiang LJ; Jiang SX; Xu YF; Zhou BB; Huang GH; Liu DM; Wang Y; Fan WZ; Li JP; Wang B
J Vasc Interv Radiol; 2019 Jul; 30(7):1004-1012. PubMed ID: 31171399
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
27. Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Cortijo J
J Comp Eff Res; 2021 Mar; 10(4):325-335. PubMed ID: 33635095
[No Abstract] [Full Text] [Related]
28. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
[TBL] [Abstract][Full Text] [Related]
29. Dacomitinib: First Global Approval.
Shirley M
Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
Takahashi T; Boku N; Murakami H; Naito T; Tsuya A; Nakamura Y; Ono A; Machida N; Yamazaki K; Watanabe J; Ruiz-Garcia A; Imai K; Ohki E; Yamamoto N
Invest New Drugs; 2012 Dec; 30(6):2352-63. PubMed ID: 22249430
[TBL] [Abstract][Full Text] [Related]
32. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
33. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y; Morita S; Sugawara S; Kato T; Fukuhara T; Gemma A; Takahashi K; Fujita Y; Harada T; Minato K; Takamura K; Hagiwara K; Kobayashi K; Nukiwa T; Inoue A;
J Clin Oncol; 2020 Jan; 38(2):115-123. PubMed ID: 31682542
[TBL] [Abstract][Full Text] [Related]
35. Management of common adverse events related to first-line dacomitinib use in
Zhou Q; Wu YL; Corral J; Nakagawa K; Garon EB; Sbar EI; Wang T; Sandin R; Noonan K; Gernhardt D; Mok TS
Future Oncol; 2019 May; 15(13):1481-1491. PubMed ID: 30839234
[No Abstract] [Full Text] [Related]
36. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F
Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910
[TBL] [Abstract][Full Text] [Related]
37. Dacomitinib Beats Gefitinib for EGFR
Cancer Discov; 2017 Aug; 7(8):OF8. PubMed ID: 28592399
[TBL] [Abstract][Full Text] [Related]
38. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
39. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]